GSK drug fails in lung patients

Share this article:

GlaxoSmithKline's immunotherapy MAGE-A3 cancer drug has failed among non-small cell lung cancer patients in a Phase III clinical trial. The company announced Thursday that the drug failed to significantly extend disease-free survival among patients its target groups. Bloomberg notes that this is the second time the drug has failed among advanced cancer patients.

The company said it is will continue with a third endpoint that was part of this trial—one that focuses on a subset of patients (those who are MAGE-A3 positive)—who may benefit from the treatment.

GSK said it is also continuing with another clinical study using this same drug, but in melanoma patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.